Vivo Capital takes majority stake in Serán Bioscience

Vivo Capital LLC acquired a majority stake in contract development and manufacturing organization Serán Bioscience.

The healthcare-focused investor made the investment together with Serán founders Dan Smithey and John Melvin, who will continue as CEO and president of the business, respectively.

Serán provides development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies.

William Blair was financial adviser to Vivo, and Latham & Watkins was legal counsel. Schwabe Williamson & Wyatt was legal adviser to Serán.